Update (June 12, 2026): Oclacitinib in Canine Sézary Syndrome — JAK1 Inhibition in a Rare CETL Subtype

TL;DR

A published case report documents temporary clinical benefit of oclacitinib in a dog with Sézary syndrome (a rare aggressive subtype of cutaneous epitheliotropic T-cell lymphoma), with tumour immunohistochemistry confirming JAK1 expression as a plausible target.

What just dropped

• Frontiers in Veterinary Science case report (2025, DOI 10.3389/fvets.2025.1645059) https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2025.1645059/full — A 10-year-old spayed female Yorkshire Terrier presented with multiple skin nodules, plaques, crusts, and pruritus. Histopathological and immunohistochemical evaluations confirmed cutaneous epitheliotropic T-cell lymphoma (CETL), and Sézary cells were identified in a peripheral blood smear confirming Sézary syndrome. Oclacitinib was initiated at an initial dose twice daily. Marked clinical improvement was observed on day 15 with disappearance of Sézary cells from peripheral blood. By day 32 the skin lesions had worsened and the oclacitinib dose was escalated. Subsequent improvements were noted within 12 days, though relapse occurred on day 63. Immunohistochemical staining revealed moderate and diffuse cytoplasmic and nuclear expression of Janus kinase 1 (JAK1), an oclacitinib target. The survival period exceeded that of previously reported canine cases of Sézary syndrome.
• EMA Apoquel EPAR https://www.ema.europa.eu/en/medicines/veterinary/EPAR/apoquel — oclacitinib maleate is the EU-authorized active substance (EMEA/V/C/002688, first positive CVMP opinion July 2013) classified under Agents for dermatitis, excluding corticosteroids. Product information last updated June 2024.

Context

Sézary syndrome is distinct from classic CETL and carries a poor prognosis; there are no established treatment guidelines in veterinary medicine. The case authors propose that oclacitinib's JAK1 inhibitory mechanism may explain the temporary responses observed, given confirmed JAK1 overexpression in the tumour cells.

This is a single case report, and results cannot be extrapolated to treatment guidelines. The primary indication for oclacitinib remains the control of pruritus and clinical signs associated with allergic and atopic dermatitis in dogs. Specific dose selection and monitoring intervals for off-label oncological use lie outside the scope of this update post; clinicians should consult oncology specialists and current formularies.

What this changes in Oclacitinib (Apoquel) for Canine Atopic Dermatitis (https://www.thevoyage.ai/forvets/knowledge/oclacitinib-canine-atopic-dermatitis)

The existing evergreen covers oclacitinib's labelled indication (pruritus in allergic and atopic dermatitis) and its JAK1/JAK3 inhibitory mechanism. This case report documents the first described off-label response in Sézary syndrome, extending the mechanistic discussion to CETL. The JAK1 immunohistochemistry finding supports the existing mechanistic description while flagging an emerging, unvalidated area of clinical interest in veterinary oncology.

Voyage Clinical Desk

From clinical question to SOAP draft — cited differentials, live dose calculators, owner handouts. Trained on the veterinary canon (Plumb's, Ettinger, JVIM, ACVIM consensus, 50,000+ indexed references). First answer free, no signup.

Open Voyage Clinical Desk: https://www.thevoyage.ai/forvets/ask?context=update-2026-06-12-oclacitinib-sezary-syndrome

References

1. (Authors listed in article). Case Report: Dose-dependent response to oclacitinib in a dog with Sézary syndrome. Front Vet Sci. 2025;12:1645059. https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2025.1645059/full
2. European Medicines Agency. Apoquel EPAR (oclacitinib maleate, EMEA/V/C/002688). Last updated June 2024. https://www.ema.europa.eu/en/medicines/veterinary/EPAR/apoquel

Changelog

• 2026-06-12: First published.

Related reads

• Oclacitinib (Apoquel) for Canine Atopic Dermatitis: JAK Inhibition and Clinical Evidence